Antidepressant Treatment Response in Depressed Hypothyroid Patients

1989 ◽  
Vol 40 (9) ◽  
pp. 954-956
Author(s):  
Mark J. Russ ◽  
Sigurd H. Ackerman
Keyword(s):  
Treatment Response ◽  
Antidepressant Treatment ◽  
Hypothyroid Patients

scholarly journals Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology

2021 ◽  
Vol 5 ◽  
pp. 247054702110142
Author(s):  
Alexandra A. Alario ◽  
Mark J. Niciu
Keyword(s):  
Treatment Response ◽  
Antidepressant Treatment ◽  
A Priori ◽  
Antidepressant Effect ◽  
Aspartate Receptor ◽  
Neurophysiological Studies ◽  
All Cause Mortality ◽  
Antidepressant Efficacy ◽  
Glutamate Modulators ◽  
Response Biomarkers

Major depressive disorder (MDD) is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide, and, unfortunately, first-line monoaminergic antidepressants and evidence-based psychotherapies are not effective for all patients. Subanesthetic doses of the N-methyl-D-aspartate receptor antagonists and glutamate modulators ketamine and S-ketamine have rapid and robust antidepressant efficacy in such treatment-resistant depressed patients (TRD). Yet, as with all antidepressant treatments including electroconvulsive therapy (ECT), not all TRD patients adequately respond, and we are presently unable to a priori predict who will respond or not respond to ketamine. Therefore, antidepressant treatment response biomarkers to ketamine have been a major focus of research for over a decade. In this article, we review the evidence in support of treatment response biomarkers, with a particular focus on genetics, functional magnetic resonance imaging, and neurophysiological studies, i.e. electroencephalography and magnetoencephalography. The studies outlined here lay the groundwork for replication and dissemination.

Assessment of mature serum brain-derived neurotrophic factor (BDNF) is not superior to total serum BDNF in prediction of antidepressant treatment outcome

2016 ◽  
Vol 33 (S1) ◽  
pp. S410-S410 ◽  
Author(s):  
A. Eckert ◽  
T. Mikoteit ◽  
J. Beck ◽  
U.M. Hemmeter ◽  
S. Brand ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Treatment Response ◽  
Rating Scale ◽  
Antidepressant Treatment ◽  
Serum Levels ◽  
Total Serum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Functional Link ◽  
Neurotrophic Activity ◽  
Serum Bdnf

BackgroundSerum BDNF levels are decreased in major depressive disorder (MDD) and tend to normalize under antidepressant treatment, serving as a treatment outcome predictor. BDNF is initially synthetized as precursor protein proBDNF and is cleaved to mature BDNF (mBDNF) while only the latter exerts neurotrophic activity.AimThe aim was to explore if a specific enzyme-linked immunosorbent assay (ELISA) kit for mBDNF in serum would be superior to the unspecific assessment of total serum BDNF in predicting treatment response in MDD.MethodsTwenty-five patients with MDD underwent standardized treatment with duloxetine. Severity of depression was measured by Hamilton Depression Rating Scale (HDRS) at baseline (BL), after one (W1), two (W2) and six weeks (W6) of treatment. Treatment response was defined as a HDRS ≥ 50% reduction of BL score at W6. mBDNF and total BDNF serum levels were determined at BL, W1 and W2.ResultsA high and stable correlation was found between mBDNF and total BDNF serum levels over all measurements. The predictive value of mBDNF BL levels and mBDNFΔW1 to response was similar to that of total BDNF BL and total BDNFΔW1. The assessment of serum mBDNF was not superior to total BDNF in prediction of treatment outcome.ConclusionsNot only baseline total BDNF but also mBDNF is predictive to treatment outcome. The later might represent the main player in this respect, which supports the idea of a functional link between neuroplasticity and MDD.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Alpha Wavelet Power as a Biomarker of Antidepressant Treatment Response in Bipolar Depression

2017 ◽  
pp. 79-94 ◽  
Author(s):  
Wojciech Jernajczyk ◽  
Paweł Gosek ◽  
Miroslaw Latka ◽  
Klaudia Kozlowska ◽  
Łukasz Święcicki ◽  
...  
Keyword(s):  
Treatment Response ◽  
Bipolar Depression ◽  
Antidepressant Treatment

Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial

2020 ◽  
pp. 1-9
Author(s):  
Yuen-Siang Ang ◽  
Gerard E. Bruder ◽  
John G. Keilp ◽  
Ashleigh Rutherford ◽  
Daniel M. Alschuler ◽  
...  
Keyword(s):  
Cognitive Control ◽  
Treatment Response ◽  
Cognitive Processing ◽  
Reuptake Inhibitor ◽  
Verbal Fluency ◽  
Antidepressant Treatment ◽  
Clinical Care ◽  
Antidepressant Response ◽  
Clinical Value ◽  
Reward Responsiveness

Abstract Background Treatment for major depressive disorder (MDD) is imprecise and often involves trial-and-error to determine the most effective approach. To facilitate optimal treatment selection and inform timely adjustment, the current study investigated whether neurocognitive variables could predict an antidepressant response in a treatment-specific manner. Methods In the two-stage Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial, outpatients with non-psychotic recurrent MDD were first randomized to an 8-week course of sertraline selective serotonin reuptake inhibitor or placebo. Behavioral measures of reward responsiveness, cognitive control, verbal fluency, psychomotor, and cognitive processing speeds were collected at baseline and week 1. Treatment responders then continued on another 8-week course of the same medication, whereas non-responders to sertraline or placebo were crossed-over under double-blinded conditions to bupropion noradrenaline/dopamine reuptake inhibitor or sertraline, respectively. Hamilton Rating for Depression scores were also assessed at baseline, weeks 8, and 16. Results Greater improvements in psychomotor and cognitive processing speeds within the first week, as well as better pretreatment performance in these domains, were specifically associated with higher likelihood of response to placebo. Moreover, better reward responsiveness, poorer cognitive control and greater verbal fluency were associated with greater likelihood of response to bupropion in patients who previously failed to respond to sertraline. Conclusion These exploratory results warrant further scrutiny, but demonstrate that quick and non-invasive behavioral tests may have substantial clinical value in predicting antidepressant treatment response.

scholarly journals The ability of early changes in motivation to predict later antidepressant treatment response

2015 ◽  
pp. 2875 ◽  
Author(s):  
Isabelle Gauthier ◽  
Philippe COURTET ◽  
Guillaume Vaiva ◽  
Emmanuelle CORRUBLE ◽  
Pierre-Michel LLORCA ◽  
...  
Keyword(s):  
Treatment Response ◽  
Antidepressant Treatment
Sign in / Sign up

Export Citation Format

Share Document